tldrdailynews.com logo

Biotech Stocks Plummet After Bone Disease Treatment Failures

1 min read
Source: Endpoints News
Biotech Stocks Plummet After Bone Disease Treatment Failures
Photo: Endpoints News
TL;DR

Ultragenyx and Mereo's late-stage clinical trial for a rare bone disease drug has failed, marking a significant setback for the development program.

Topics:business#bone-disease#business#drug-failure#late-stage#mereo#ultragenyx
Share this article
  1. Ultragenyx, Mereo crash on late-stage bone disease failure  Endpoints News
  2. Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate  Reuters
  3. Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta  Yahoo Finance
  4. These biotech stocks are getting hammered by shocking brittle-bone treatment study results  MarketWatch
  5. Ultragenyx vows 'significant' cutbacks as failed study wipes more than $1 billion from Novato biotech's market value  The Business Journals

Want the full story? Read the original reporting

Read on Endpoints News